TAVR in Patients with Moderate Aortic Stenosis with At-Risk Features
Authors, Journal, Affiliations, Type, DOI
- Philippe Généreux, Raj R. Makkar, Philippe Pibarot, Jeroen J. Bax, Brian R. Lindman, and co-authors for the PROGRESS Trial Investigators; lead site Atlantic Health, Gagnon Cardiovascular Institute at Morristown Medical Center, New Jersey.
- 74 sites in six countries (87.1% United States; also Japan, Australia, the Netherlands, Canada and Switzerland).
- The New England Journal of Medicine, published November 2, 2026.
- Type: international, multicentre, open-label, randomized controlled superiority trial with blinded core laboratories and an independent clinical-events committee.
- DOI: 10.1056/NEJMoa2607326. ClinicalTrials.gov: NCT04889872.
- Funded by Edwards Lifesciences; the sponsor participated in protocol development with the steering committee, the FDA and the investigators.
Overview
PROGRESS randomized 744 patients aged 65 years or older with moderate aortic stenosis and at least one at-risk feature to transfemoral TAVR with a balloon-expandable SAPIEN 3 platform or guideline-recommended clinical surveillance. At two years the composite of death from any cause or a heart-failure event occurred in 16.7% with TAVR and 23.9% with surveillance (risk difference −7.2 percentage points; hazard ratio 0.67, 95% CI 0.48–0.93; P=0.02). The benefit was driven by heart-failure events and hospitalization, not by mortality, which was 8.4% versus 7.3%. The trial therefore converts a heterogeneous "moderate" label into an actionable phenotype defined by at-risk features, and does so despite 57.4% of the surveillance arm undergoing aortic-valve replacement within two years.
Keywords
Moderate aortic stenosis, transcatheter aortic-valve replacement, clinical surveillance, at-risk features, heart-failure hospitalization, aortic-valve calcium score, left ventricular ejection fraction, diastolic dysfunction, randomized controlled trial
Key Takeaways
Background and Rationale
- Guidelines recommend clinical surveillance with echocardiography every 1–2 years for moderate aortic stenosis until stenosis becomes severe or another indication for surgery appears.
- Moderate aortic stenosis is heterogeneous: some patients progress rapidly and have a prognosis resembling severe stenosis, particularly those with symptoms, structural or functional abnormalities, or elevated calcium scores.
- PROGRESS was designed to test whether earlier TAVR improves outcomes in the moderate-AS population selected for at least one such at-risk feature.
Methods
- Eligibility: age ≥65 years, echocardiographic moderate aortic stenosis, and at least one at-risk feature — valve-related symptoms (NYHA class II or higher, chest pain or syncope), LVEF <60%, grade ≥2 diastolic dysfunction, stroke volume index <35 mL/m², persistent or paroxysmal AF within 6 months, NT-proBNP greater than three times the upper limit of normal, or an elevated aortic-valve calcium score (>1200 Agatston units in women, >2000 in men).
- Exclusions included LVEF <20% and clinically significant untreated coronary disease warranting revascularization.
- Randomized 1:1 to transfemoral TAVR with SAPIEN 3, SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA, or clinical surveillance with guideline-directed management.
- Primary effectiveness endpoint: non-hierarchical composite of death from any cause or a heart-failure event, with or without hospitalization, at 2 years in the intention-to-treat population.
- Primary safety endpoint at 30 days: death, stroke, life-threatening or fatal bleeding, stage 4 acute kidney injury, hospitalization for a device- or procedure-related complication, or valve dysfunction leading to reintervention; tested against a prespecified 13.7% performance goal.
- Secondary endpoints were tested hierarchically: death, stroke or HF hospitalization; alive with a sustained ≥10-point KCCQ-OS improvement at 1 and 2 years; HF hospitalization; LV mass index; grade ≥2 diastolic dysfunction.
Patients
- 1,294 patients screened, 744 randomized (373 TAVR, 371 surveillance); enrolment October 2021 to January 2024.
- Mean age 78.4 years; 39.1% women; mean STS-PROM 3.0%; 45.6% at low surgical risk by local heart-team assessment.
- Mean aortic-valve area 1.2 cm²; mean peak velocity 3.3 m/s; mean gradient 25.1–25.4 mmHg; 91.6% had concordant moderate disease.
- Median aortic-valve calcium score 1,209 Agatston units; bicuspid valve in 7.4%.
- Valve-related symptoms in 96.4%; grade ≥2 diastolic dysfunction in 43.8%; 72% had at least two at-risk features and 40% at least three.
- Mean KCCQ-OS 64.2; 35.5% in NYHA class III or IV.
Primary Endpoints
- Primary effectiveness event at 2 years: 60 patients (16.7%) with TAVR versus 85 (23.9%) with surveillance; risk difference −7.2 percentage points (95% CI −13.1 to −1.3; P=0.02 for superiority); hazard ratio 0.67 (95% CI 0.48–0.93).
- Death from any cause: 8.4% versus 7.3% (hazard ratio 1.14, 95% CI 0.67–1.93).
- Heart-failure event with or without hospitalization: 10.8% versus 19.0% (hazard ratio 0.55, 95% CI 0.37–0.81).
- Primary safety endpoint at 30 days in 21 of 358 treated patients (5.9%; 95% CI 3.9–8.8), below the 13.7% performance goal (P<0.001).
Secondary and Additional Outcomes
- Death, stroke or HF hospitalization: 17.7% versus 23.3% (difference −5.6 percentage points, 95% CI −11.5 to 0.3; P=0.07), so hierarchical testing stopped at this step.
- Alive with a sustained ≥10-point KCCQ-OS improvement at 1 and 2 years: 39.0% versus 23.2% (difference 15.7 percentage points, 95% CI 8.8–22.6).
- HF hospitalization: 7.4% versus 14.9% (difference −7.5 percentage points, 95% CI −12.2 to −2.9); annualized HF hospitalization rate 6.2 versus 12.0 events per 100 patient-years (hazard ratio 0.52, 95% CI 0.35–0.78).
- LV mass index 97.1±28.3 versus 101.1±30.1 g/m²; grade ≥2 diastolic dysfunction 38.9% versus 36.5% (no significant difference).
- No apparent difference in myocardial infarction or stroke.
- NYHA class III–IV at 2 years: 3.9% versus 10.9%; mean KCCQ-OS 79.4 versus 73.8, with a within-patient increase of 14.3 versus 7.7 points.
Progression in the Surveillance Arm
- 99 patients (27.0%) underwent delayed aortic-valve replacement within 1 year and 204 (57.4%) within 2 years.
- The reason was progression to severe AS with a class 1 indication in 166 of 204 patients (81.4%); 199 of 204 (97.5%) had TAVR and 5 (2.5%) surgery.
- From baseline to delayed replacement, mean peak velocity rose 0.5 m/s, mean gradient rose 10.5 mmHg, valve area fell 0.3 cm², and KCCQ-OS fell 9.3 points.
Procedural Outcomes
- Thirty-day mortality after TAVR was 0% in the TAVR arm and 0.5% after delayed replacement in the surveillance arm; stroke 0.8% versus 2.5%.
- New permanent pacemaker implantation 13.0% versus 10.4%; most had pre-existing right or left bundle-branch block.
- Moderate or greater paravalvular regurgitation at 30 days: 0% after index TAVR and 0.5% after delayed replacement.
Interpretation
- TAVR was superior to surveillance for the composite endpoint even though most surveillance patients eventually underwent valve replacement, suggesting that the timing of intervention — and the heart-failure events occurring while waiting — carries the difference.
- The result contrasts with TAVR UNLOAD, which enrolled patients with reduced LVEF and was not powered for its primary endpoint; PROGRESS enrolled a predominantly preserved-LVEF population selected by at-risk features.
- Approximately 16% of consenting patients thought to have moderate AS by referring physicians were ultimately found to have lesser or greater disease severity, supporting prompt referral to a dedicated valve clinic.
Limitations of the Document
- Open-label design; the clinical-events committee was aware of group assignment, which may introduce observer or reporting bias.
- Findings are restricted to patients aged ≥65 years who were suitable for transfemoral TAVR with the trial valve; applicability to patients without at-risk features is unknown.
- The trial was not designed to determine whether earlier intervention changes mortality; death was numerically, non-significantly higher with TAVR.
- Medical therapy for heart failure was not protocolized, and guideline-directed therapy for HFpEF was evolving during enrolment; SGLT2 inhibitor recommendations were published after enrolment began.
- The high rate of delayed valve replacement in the surveillance arm may have attenuated the observed benefit of early TAVR.
Key Concepts Mentioned
- concepts/Moderate-Aortic-Stenosis — the population, at-risk features and trial result
- concepts/Aortic-Stenosis — grading, staging and indications for intervention
- concepts/Valvular-Heart-Disease — the parent disease framework
- concepts/TAVI — procedural platform and trial context
- concepts/HFpEF-Management — heart-failure events in a predominantly preserved-LVEF population
Key Entities Mentioned
- entities/Bicuspid-Aortic-Valve — present in 7.4% of the trial population
- entities/Heart-Failure — the competing clinical outcome during surveillance
Wiki Pages Updated
wiki/sources/TAVR-ModAS-NEJM-2026.md— created (this file)wiki/concepts/Moderate-Aortic-Stenosis.md— createdwiki/concepts/Aortic-Stenosis.md— updated with the PROGRESS result and a linkwiki/concepts/Valvular-Heart-Disease.md— updated with a moderate-AS trial referencewiki/wikiindex.md— updatedwiki/sourceindex.md— updated